Truist Financial’s Krystal Biotech KRYS Stock Holding History

Truist Financial’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$659K	Buy	1,773 +609	+52%	+$182K	﹤0.01%	2027
2026 Q1	$301K	Buy	1,164 +84	+8%	+$22.4K	﹤0.01%	2396
2025 Q4	$266K	Buy	+1,080	New	+$227K	﹤0.01%	2410
2022 Q1	–	Sell	-4,000	Closed	-$280K	–	2763
2021 Q4	$280K	Hold	4,000	–	–	﹤0.01%	2402
2021 Q3	$209K	Hold	4,000	–	–	﹤0.01%	2540
2021 Q2	$272K	Hold	4,000	–	–	﹤0.01%	2426
2021 Q1	$308K	Hold	4,000	–	–	﹤0.01%	2268
2020 Q4	$240K	Buy	+4,000	New	+$200K	﹤0.01%	2295
2020 Q3	–	Sell	-11,000	Closed	-$456K	–	2498
2020 Q2	$456K	Hold	11,000	–	–	﹤0.01%	1669
2020 Q1	$476K	Hold	11,000	–	–	﹤0.01%	1587
2019 Q4	$609K	Buy	+11,000	New	+$540K	﹤0.01%	1723

Other funds holding KRYS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Truist Financial's KRYS Position: Q2 2026 in Review

Truist Financial increased its Krystal Biotech (KRYS) stake by 52% in Q2 2026, buying an estimated $182K and bringing the position to 1,773 shares worth $659K. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

Truist Financial first reported a position in KRYS in Q4 2019 and has held it in 11 quarters since. 191 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Truist Financial held 1,773 shares of Krystal Biotech worth $659K as of Q2 2026.
Truist Financial bought 609 Krystal Biotech shares in Q2 2026, an estimated $182K.
Krystal Biotech made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2027 holding.
Truist Financial first reported a position in Krystal Biotech in Q4 2019 and has held it in 11 quarters since.
191 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.